ArticleThe Lancet. Infectious diseases2021
Lung fibrosis: an undervalued finding in COVID-19 pathological series.
Article in The Lancet. Infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed.
- A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models.Nature biotechnology · 2025Trial
- SARS-CoV-2-encoded miR-nsp3-3p promotes pulmonary fibrosis by inhibiting expression of ALCAM.Virologica Sinica · 2025Article
- The respiratory microbiome in patients with post-COVID-19 residual lung abnormalities resembles that of healthy individuals and is distinct from idiopathic pulmonary fibrosis.ERJ open research · 2025Article
- Understanding of Patients with Severe COVID-19 Using Lung Ultrasound.Tuberculosis and respiratory diseases · 2025Article
- Targeting pleuro-alveolar junctions reverses lung fibrosis in mice.Nature communications · 2025Article
- Convergent and divergent immune aberrations in COVID-19, post-COVID-19-interstitial lung disease, and idiopathic pulmonary fibrosis.American journal of physiology. Cell physiology · 2025Article
- Revisiting pulmonary fibrosis: inflammatory dynamics of the lipofibroblast-to-inflammatory lipofibroblast-to-activated myofibroblast reversible switch.Frontiers in immunology · 2025Review
- Influenza, SARS-CoV-2, and Their Impact on Chronic Lung Diseases and Fibrosis: Exploring Therapeutic Options.The American journal of pathology · 2024Review
- Association of pulmonary function test abnormalities and quality-of-life measures after COVID-19 infection.The American journal of the medical sciences · 2024Article
- Sinomenine attenuates pulmonary fibrosis by downregulating TGF-β1/Smad3, PI3K/Akt and NF-κB signaling pathways.BMC pulmonary medicine · 2024Article
- Imaging in the diagnosis and management of fibrosing interstitial lung diseases.Breathe (Sheffield, England) · 2024Review
- Prevalence of Long COVID Symptoms Related to SARS-CoV-2 Strains.Life (Basel, Switzerland) · 2023Article
- Article
- Pulmonary fibrosis: A short- or long-term sequelae of severe COVID-19?Chinese medical journal pulmonary and critical care medicine · 2023Review
- Post-COVID Interstitial Lung Disease-The Tip of the Iceberg.Immunology and allergy clinics of North America · 2023Review
- The pulmonary vasculature in lethal COVID-19 and idiopathic pulmonary fibrosis at single-cell resolution.Cardiovascular research · 2023Article
- Review
- Studying pulmonary fibrosis due to microbial infectionFrontiers in microbiology · 2023Article
- Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model.Antiviral research · 2023Article
- Chest CT in covid-19 pneumonia's follow-up: A 30 patients case series.Annals of medicine and surgery (2012) · 2022Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Comment on
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.